DIA
NBIX icon

Dana Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Dana Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.2M Buy
+36,763
New +$5.45M 0.16% 159
2019
Q3 		– Sell
-3,005
Closed -$254K – 278
2019
Q2 		$254K Buy
+3,005
New +$247K 0.01% 265

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dana Investment Advisors's NBIX Position: Q2 2026 in Review

Dana Investment Advisors opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 36,763 shares worth $6.2M. The stake represents 0.16% of the portfolio and ranks #159 among its holdings. This is a return to the name: Dana Investment Advisors previously reported a position in NBIX as recently as Q2 2019.

Dana Investment Advisors first reported a position in NBIX in Q2 2019 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Dana Investment Advisors held 36,763 shares of Neurocrine Biosciences worth $6.2M as of Q2 2026.
  • Neurocrine Biosciences was a new Dana Investment Advisors position in Q2 2026.
  • Neurocrine Biosciences made up 0.16% of Dana Investment Advisors's portfolio in Q2 2026, its #159 holding.
  • Dana Investment Advisors first reported a position in Neurocrine Biosciences in Q2 2019 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Dana Investment Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.